8-K: Bristol Myers Squibb Reports Strong Q4 and Full-Year 2024 Results, Driven by Growth Portfolio

Bristol Myers Squibb's Q4 2024 revenues increased by 8% to $12.3 billion, driven by its Growth Portfolio, while providing 2025 revenue guidance of approximately $45.5 billion.

Summary

• Bristol Myers Squibb (BMS) reported its fourth quarter and full-year financial results for 2024.
• Fourth-quarter revenues reached $12.3 billion, an increase of 8% (9% adjusting for foreign exchange).
• GAAP earnings per share (EPS) was $0.04, while non-GAAP EPS was $1.67.
• Growth Portfolio revenues were $6.4 billion, representing a 21% increase (23% adjusting for foreign exchange).
• Full-year revenues amounted to $48.3 billion, a 7% increase (9% adjusting for foreign exchange).
• GAAP loss per share was $(4.41), and non-GAAP EPS was $1.15, including a net impact of $(6.39) per share due to acquired IPRD charges and licensing income.
• Growth Portfolio revenues for the full year were $22.6 billion, a 17% increase (19% adjusting for foreign exchange).
• The company achieved multiple clinical and regulatory milestones in the fourth quarter, including U.S. approval of Opdivo Qvantig and the U.S. launch of Cobenfy.
• BMS is expanding its strategic productivity initiative to deliver approximately $2 billion in additional cost savings by the end of 2027.
• The company provides 2025 guidance with revenues of approximately $45.5 billion and a non-GAAP EPS range of $6.55 to $6.85.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. While there are challenges related to generic competition and GAAP losses, the strong growth in the Growth Portfolio, cost-saving initiatives, and positive clinical and regulatory milestones contribute to a favorable outlook.

Positives

• Strong growth in the Growth Portfolio, driven by higher demand for key products like Reblozyl, Breyanzi, Camzyos, Yervoy, and Opdualag.
• U.S. approval of Opdivo Qvantig and the U.S. launch of Cobenfy.
• Expansion of the strategic productivity initiative to generate additional cost savings.
• FDA PDUFA goal date for Camzyos to reduce the frequency of required echocardiography monitoring once a patient treated for obstructive hypertrophic cardiomyopathy is on a stable dose.
• The CHMP of the EMA recommended approval of Breyanzi for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) who have received two or more prior lines of systemic therapy.

Negatives

• GAAP loss per share for the full year was $(4.41).
• Decrease in gross margin on a GAAP basis, primarily driven by intangible asset impairment charges and product mix.
• The company anticipates a revenue decline of approximately 18-20% in the Legacy Portfolio due to the impact of generics.
• The company expects an approximate $500 million negative impact to revenue due to foreign exchange.

Risks

• Increasing pricing pressures from market access, pharmaceutical pricing controls, and discounting.
• Potential difficulties and delays in product introduction and commercialization.
• Increasing industry competition.
• The failure of the company's suppliers, vendors, outsourcing partners, alliance partners and other third parties to meet their contractual, regulatory and other obligations.
• The impact of the company's significant indebtedness.
• Political and financial instability of international economies and sovereign risk.

Future Outlook

Bristol Myers Squibb anticipates total revenues of approximately $45.5 billion in 2025, reflecting the impact of generics on the Legacy Portfolio, partially offset by the continued strength of the Growth Portfolio. The company expects non-GAAP EPS to be in the range of $6.55 to $6.85.

Management Comments

• We made good progress in 2024, which was capped by a fourth quarter of strong topline growth driven by key products and important pipeline advancements, said Christopher Boerner, Ph.D., board chair and chief executive officer, Bristol Myers Squibb.
• We also achieved the landmark U.S. approval of Cobenfy last year for the treatment of schizophrenia in adults, and we expect this medicine to have a meaningful impact on patients and the company as a new growth driver.
• Our collective focus on execution has established a solid foundation to navigate the multi-year journey toward achieving top-tier sustainable growth and long-term shareholder returns.

Industry Context

The report reflects the ongoing shift in the pharmaceutical industry towards innovative, high-growth products, as companies face increasing competition from generics for older drugs. BMS's focus on its Growth Portfolio and strategic acquisitions aligns with this trend, as companies seek to maintain revenue growth and profitability.

Comparison to Industry Standards

• The growth in Bristol Myers Squibb's Growth Portfolio is comparable to the strategies employed by other major pharmaceutical companies like Pfizer and Merck, who are also focusing on key growth drivers to offset revenue losses from patent expirations.
• The strategic productivity initiative to deliver ~$2 billion in additional cost savings by the end of 2027 is similar to cost-cutting measures announced by other large pharmaceutical companies to improve efficiency and profitability.
• The company's focus on business development and capital allocation mirrors the approach of companies like AbbVie, which have used strategic acquisitions to diversify their product portfolio and drive growth.

Stakeholder Impact

• Shareholders: Potential for long-term value creation through growth initiatives and strategic capital allocation.
• Employees: Organizational design changes as part of the strategic productivity initiative may impact workforce structure.
• Patients: Access to innovative medicines and therapies for serious diseases.
• Customers: Continued supply of existing products and introduction of new therapies.
• Suppliers: Ongoing relationships for the supply of materials and services.

Next Steps

• Continue to advance the Growth Portfolio with double-digit sales growth.
• Expand opportunities with Cobenfy with potential multi-billion-dollar peak sales over the decade.
• Achieve key milestones in 2025-2027, including data readouts for Reblozyl, Opdualag, Camzyos, Cobenfy, Iberdomide, and others.
• Realize additional cost savings of approximately $2 billion by the end of 2027 through the expanded strategic productivity initiative.
• Pursue opportunities and partnerships to diversify the portfolio and strengthen the long-term outlook.

Key Dates

Keywords

Revenues, Growth Portfolio, Financial Results, Bristol Myers Squibb, EPS, Cobenfy, Opdivo, Breyanzi